Phase 2 Treatment of Adults With Primary Malignant Glioma With Karenitecin
Interventional
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Objective Tumor Response Rate
Randomization to end of treatment
No
United States: Food and Drug Administration
KTN20405
NCT00062478
October 2001
Name | Location |
---|---|
For Information call 210-614-1701 for a site near you | Durham, North Carolina 27710 |